Elena Prado-Mel

#HospitalPharmacist

[Yakup Ergün @dr_yakupergun]

#ASCO26

Does CDK4/6i really work in ER-low disease?

I had also really wanted to study the efficacy of CDK4/6 inhibitors in ER-low tumors, but I could not collect enough data. This study addresses exactly this important question. First of all, congratulations to the investigators.

In ER-low HR+/HER2− MBC, CDK4/6i + ET does not seem to deliver the expected HR+ benefit: PFS was 2.9 months. In ER-high patients, PFS was 23.3 months.

Despite the small sample size and the inherent limitations of a retrospective study, the observed behavior is consistent with what we would expect from ER-low tumors. ER-low disease should not simply be placed into the classic HR+ category with automatic CDK4/6i + ET. This subtype behaves closer to TNBC.

[Erman Akkus @Erman_Akkus]

Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapy - European Journal of Cancer https://t.co/5RKDhmfrKa

[S.E.F.H @sefh_]

Clausuramos el I Título Experto en Medicina Personalizada de Precisión para Farmacia Hospitalaria @sefh_ @ufvmadrid con colab. @AstraZenecaES

Una formación pionera para preparar a los farmacéuticos/as de hospital ante el nuevo paradigma de la medicina personalizada, incorporando genómica, farmacogenética, IA y terapias avanzadas a la práctica clínica 🧬💊

Gracias a alumnado, profesorado y coordinación científica por impulsar esta primera edición 👏

[Paolo Tarantino @PTarantinoMD]

The approval of T-DXd for the (neo)adjuvant treatment of HER2+ breast cancer will add an invaluable tool to our arsenal. Yet, in this era of right-sizing, not all patients require T-DXd treatment to be cured. Some thoughts in my recent JCO editorial. https://t.co/tKCgzzbdiq

[Farmacia HUVR @FarmaciaHUVR]

Equipazo del grupo de investigación de #FarmaciaYFarmacocinéticaClínica del #IBiS. ¡Lo pasamos genial!. 24FeriaDeLaCiencia, celebrada en el #PalaciodeCongresosYExposicionesSevilla https://t.co/WXks6ykfVa

[María Jiménez-Meseguer @M_Jimenez1408]

Mucho trabajo y un equipo maravilloso detrás de este artículo:

Early Pembrolizumab Plasma Levels as a Prognostic Biomarker in Real-Wo... https://t.co/xTWvCTtksa

[Elena Prado-Mel @Epramel]

Muy contenta de compartir el segundo artículo del proyecto OncoNutriDos
@GrupoNutri @sefh @gedefo_sefh
🔬 Estudio multicéntrico
💊 Proyecto SEFH

https://t.co/QLpGXdQoCT

[Elena Prado-Mel @Epramel]

Muy contenta de compartir el segundo artículo del proyecto OncoNutriDos
@GrupoNutri @sefh @gedefo_sefh
🔬 Estudio multicéntrico
💊 Proyecto SEFH

https://t.co/QLpGXdQoCT

[Dr Rishabh Jain @DrRishabhOnco]

🚨 FDA’s take on SERENA-6 is basically this:
“Nice data… but are we helping patients?”

Let’s break it down 👇

🧠 Problem 1: Wrong question

Trial asks:
👉 Switch early vs don’t switch

But real-world question is:
👉 Switch early vs switch later
FDA:
❌ “You didn’t answer the real question.”

⏱️ Problem 2: The PFS illusion

PFS looks great (16 vs 9.2 months)

But… it starts from:
👉 ESR1 mutation detection (not progression)

FDA:
❓ “What does this PFS even mean clinically?”

🧬 Problem 3: Biology mismatch

We assume: ESR1 mutation = resistance

FDA says:
👉 Not so fast

Patients may still benefit from AI + CDK4/6i
even AFTER mutation appears

👉 Early switch = stopping a working drug

🔁 Problem 4: No second chance

Control arm never got camizestrant later ❌

So we don’t know:
👉 Early vs delayed use

FDA:
❌ “This comparison is incomplete”

📉 Problem 5: Where is survival benefit?

OS = immature
Final data → years away

FDA:
👉 “Without OS, paradigm shift is risky”

⚠️ Problem 6: Not risk-free

QT prolongation
Bradycardia
Rare TdP

👉 Not a harmless switch

🎯 FDA’s real message:

“Just because we can act early…
doesn’t mean we should.”

🔖 Save this - this is how regulators think

📖 Full FDA briefing in comment ⬇️

#OncoTwitter #MedTwitter #BreastCancer #ESMOBreast26
@OncoAlert @myesmo @esmo_open @asco @OncBrothers

[JAMA Oncology @JAMAOnc]

First-line CDK4/6 inhibitor use did not improve overall survival vs second-line use in advanced hormone receptor–positive, ERBB2-negative #BreastCancer and increased grade ≥3 adverse events.

https://t.co/HFpuBhUexu

[S.E.F.H @sefh_]

👉👉👉 La conclusión es clara: NO existe evidencia científica publicada que avale la eficacia de la homeopatía en ninguna patología

🔗 Consulta el informe @AEMPSGOB "Homeopatía y productos homeopáticos: Evaluación de las evidencias acerca de su eficacia y seguridad" https://t.co/jfheLLg6WE

[Yakup Ergün @dr_yakupergun]

One of the most notable studies from #AACR26:

Daraxonrasib + gem/nab-paclitaxel shows a strong early signal in 1L mPDAC.

ORR 58%
DCR 90%
6-month PFS 84%!!

Things are finally moving in pancreatic cancer👇

https://t.co/ijyGOW6hmE

[AstraZeneca España @AstraZenecaES]

Impulsamos Elevating Healthcare Leaders junto a @IEuniversity, una jornada centrada en Farmacia Hospitalaria para explorar la IA aplicada a la salud, medicina de precisión y excelencia operativa, conocimientos que otorgan una clara ventaja competitiva en el complejo y cambiante sector sanitario.

[Elena Prado-Mel @Epramel]

@HospitalUVRocio Enhorabuena Antonio 👏🏻👏🏻👏🏻

[S.E.F.H @sefh_]

📢🎓Mañana martes 14 de abril a las 8:30h... os esperamos en las Sesiones Formativas Online - Módulo 9

10ª sesión: 🗓 Evaluación de medicamentos: ¿y ahora qué? - Eduardo López Briz @lopez_briz @GENESIS_SEFH

💻Accede con las claves de socio/a SEFH: https://t.co/MPIYgQ7iSJ

[Elena Prado-Mel @Epramel]

@ucihuvr @SaludConsumoSe @HospitalUVRocio @semicyuc 👏🏻👏🏻👏🏻

[S.E.F.H @sefh_]

🎯 🧪 🆕 Mapeo Nacional de Grupos de Investigación liderados por Farmacéuticos Hospitalarios

Desde la SEFH buscamos conocer la distribución de los grupos, líneas de trabajo y capacidades para impulsar colaboraciones y avanzar hacia una posible Red Nacional de Investigación en FH

📋 Participa aquí: https://t.co/4R8zyP58p5

¡Contamos contigo! 🚀

[Karamvir Yadav @K_Yadavir]

TACO Trial

Tri-weekly cisplatin (75 mg/m² q3w) vs weekly cisplatin (40 mg/m²) with concurrent RT in LACC.

Results:
• No difference in RFS or OS
• Similar recurrence patterns
• Lower hematologic toxicity with tri-weekly dosing

Clinical takeaway:
Tri-weekly cisplatin is a valid alternative regimen.

#CervicalCancer #OncologyResearch @OncoAlert @oncodaily @DrBarbiOnc @CCAENetwork @myESMO @ValenzaCarmine @stolaney1

[Yüksel Ürün @DrYukselUrun]

Obesity and Cancer:
Obesity can reshape inflammation, hormones, immunity, and metabolism in ways that help tumors grow. Preventing obesity is also part of cancer prevention.
@JAMA_current #obesity #cancer @OncoAlert @MedicalwatchHQ

[Yakup Ergün @dr_yakupergun]

Taxanes, EGFR inhibitors and multikinase inhibitors are the main drivers of nail toxicities in oncology. Early nail care, cryotherapy during taxanes, and prompt treatment of paronychia (topical steroids/antibiotics) can prevent infections and avoid unnecessary treatment interruptions

https://t.co/FlfFCzzu6F